Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
TVTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.12 - $25.29
Previous CloseN/A
Volume140.04K
Average Volume (3M)1.77M
Market Cap
$1.41B
Enterprise Value$1.48B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.84
Next Earnings
May 01, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.10
Shares Outstanding88,771,680
10 Day Avg. Volume1,653,138
30 Day Avg. Volume1,770,482
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.81
Price to Cash Flow (P/CF)-12.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.34
Enterprise Value/Ebitda-5.56
Forecast
1Y Price Target
$34.91Price Target Upside98.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageFilspari on strong footing versus atrasentan, with PROTECT trial showing better proteinuria reduction and more comprehensive data at launch.
Market PotentialPotential approval in focal segmental glomerulosclerosis/FSGS could open Filspari up to another large market, with virtually zero competition.
Regulatory ApprovalFDA opens the door for a Filspari sNDA filing, with existing data from the DUPLEX and DUET studies providing additional context.
Bears Say
Market BarriersFilspari’s monthly monitoring is a significant barrier to uptake, particularly for those in rural or community settings.
Regulatory RequirementsConcerns over its positioning due to the requirement of REMS for Filspari, which has slowed uptake.
Safety ConcernsFilspari carries a black box warning for hepatotoxicity and a monitoring requirement.
---
Ownership Overview
1.47% Insiders
22.23% Mutual Funds
0.47% Other Institutional Investors
60.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $5.12 and its highest was $25.29 in the past 12 months.
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is $1.41B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 6 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Feb 20, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.562 by -$0.168.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -0.57.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 88,771,680 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.562. Following the earnings report the stock price went down -6.785%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in TVTX
---
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.91 (98.01% Upside)
$34.91 (98.01% Upside)
Blogger Sentiment
Bullish
TVTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
190.94%
12-Months-Change
Fundamentals
Return on Equity
-246.75%
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
---
TVTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with significant achievements such as FDA approval and sales growth of FILSPARI, expansion plans into FSGS indication, and strong financial performance. However, challenges remain with declining sales of Thiola due to generic competition and a substantial net loss for the year.Read More>---
TVTX Stock 12 Month Forecast
Average Price Target
$34.91
▲(98.01% Upside)
Technical Analysis
BioCryst
―
Disc Medicine
―
Immunocore Holdings
―
Vera Therapeutics
―
CG Oncology, Inc.
―
Best Analysts Covering TVTX
1 Year
1 Year Success Rate
10/18 ratings generated profit
1 Year Average Return
+28.37%
reiterated a buy rating 16 days ago
Copying Edward Nash's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +28.37% per trade.
---